As a chief technology officer at a biotech venture capital firm, neuroscientist Elizabeth Hudson frequently analyzed industry trends to support portfolio companies. “You learn a ton doing that, and one of the things you learn is that the data landscape is terrible,” said Hudson. “It's voluminous and yet totally inadequate.”
While massive datasets exist for animal models of specific diseases, Hudson noted that data representing healthy human bodies remain scarce. According to her, this is partly because the pharmaceutical industry operates in vertical silos, with companies trying to master all the steps in either prevention, diagnostics, or therapeutics.
“The analogy I like to use is…think about an airline,” she said, noting that airlines have to ace scheduling flight crews, selling tickets, maintaining planes, and advertising. “They can't also be hiring geologists to go drill wells to extract oil to refine into jet fuel.”
Similarly, Hudson argued that biotech companies spend a lot of resources on obtaining data, which could divert their energies from focusing on their core operations.

Elizabeth Hudson is the CEO and founder of Ambitious Bio.
Winni Wintermeyer
This motivated her to found Ambitious Bio to generate original, raw proteomics data from human postmortem tissue samples, which allow researchers to probe at a deeper level compared to samples obtained from living donors. The company recently launched Corpus, the world’s largest healthy human protein atlas. It offers a reference that teams training AI tools can harness to better understand the human body, helping researchers design better biomedical interventions.
Postmortem Tissue Proteomics Shines Light on Hidden Protein Targets
The focus on proteomics was deliberate, explained Hudson. Although researchers have a glut of genomics data, “We know very little about the healthy body at the proteomics level,” she said.
The proteomics gap is particularly glaring considering that many drugs target proteins, Hudson said. However, current drug discovery efforts focus on only a fraction of the hundreds of thousands of proteins produced in the human body. “The universe is full of dark matter,” said Hudson. “There's opportunity out there; we just can't see [it].”
To bring this “dark proteome” into the limelight, Hudson and her colleagues turned to postmortem tissue samples from healthy, non-diseased donors. They focused on healthy samples because, “No matter what disease you're treating, you must know what the healthy body looks like, because your drug is not allowed to nuke the healthy body,” explained Hudson.

Researchers at Ambitious Bio also carried out mass spectrometry on human aortic tissue to build a reference proteome.
Ambitious Bio
The researchers obtained frozen cadaver tissue samples and subjected multiple tissues from each donor to mass spectrometry. This helped them identify up to 12,000 proteins per tissue sample. This information expanded the Human Protein Atlas—the field’s most commonly used reference—by 56 percent. This means that Corpus offered information on 56 new proteins in each tissue for 100 that were already known. In fact, in all tissue types compared between Corpus and the Human Protein Atlas, the former detected expression of at least one potential drug target that the latter had missed.
Expanding the Reference Landscape
While the researchers only obtain proteomics data at the moment, they eventually plan to expand their datasets. Matching proteomics results with those from RNA sequencing, whole-genome sequencing, histopathology, transcriptomics, biofluids, and electronic health records of each donor can help obtain a fuller picture of their overall health, noted Hudson.
Moreover, the current data are drawn only from healthy, non-diseased donors, which provides a reference for baseline. By next year, Hudson and her colleagues plan on expanding this to enroll diseased donors to obtain insight into how healthy protein landscapes differ from those in diseased states. This could offer clues into disease-specific drug targets, pointing drug discovery companies in directions to pursue investigations with less uncertainty and financial risk.
“There are people waiting for cures right now,” said Hudson. “If we have any hope of providing better products to people faster and at prices that don't bankrupt folks…better data collection is the only route.”
Zooming out, while Hudson noted that Ambitious Bio does not plan to design, develop, or sell drugs, the company’s vision is to offer raw data upon which these discoveries can be built. “We are like the underground sewer [system] without which those skyscrapers don't run, but you never see [us],” said Hudson.
















